ABOUT THE EVENT
Respiratory Drugs Hybrid Summit: from Development to Delivery – This conference was designed with a primary focus on knowledge exchange, catering exclusively to industry leaders and decision-makers. Experts in the fields of Drug Delivery Technologies, Respiratory Pharmacology, Inhalation Devices, Outsourcing, Inhalation Product Development and Manufacturing, Equipment, Inhaled Formulation Science, Regulations and many other related areas will be in attendance.
This cutting-edge conference will focus on the latest developments and trends in the Pharma industry. With the pharmacological and biotechnical markets constantly changing and evolving, our expert speakers will address the challenges that can be faced, and cover a wide range of topics, such as: Novel technologies for pulmonary & nasal delivery, Innovative Development of Inhalation devices, Dry-powder Inhalers (DPIs) and Metered-dose inhalers (MDIs), Model Validation, Pharma 4.0, Digitalization, Smart and Digital Inhalers and Sustainable Manufacturing.
Become a part of this unique event with great opportunities for both live and virtual meetings. It is our goal to provide a platform that reaches the largest possible audience and promotes effective networking for our attendees. We understand that companies have different travel policies and potential travel restrictions, so in order to prevent limitations on attendance, we will be holding this conference in a hybrid format.
We will be waiting for you in the beautiful city of Munich on 13th – 14th October, 2022!
CONFERENCE LEARNING POINTS
- Updates in Regulations
- Smart and Digital inhalers
- Design & Functionality in DPI/MDI/Generic Products
- Micronization: of The API/Drug
- Continuous Improvement of Extractable & Leachable
- Manufacturing of delivery devices
- Requirements for Single-Dose Reusable Inhalers
- Development of OINDPs
- Overcoming key formulation challenges for small molecules
With unparalleled diagnostics and drug development capabilities, they accelerate innovation and provide insight to improve health and improve lives. Whether they’re a patient, provider, researcher or in the pharmaceutical industry, they’re here for you. More than 70,000 employees strong, they serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY 2020.
Founded in 1870 by the Vincentian Community, St. John's is known for giving students the knowledge, skills and confidence to serve others while achieving personal and professional success. Graduates become leaders in their professions, their communities and the world.
With three friendly, residential campuses in New York, St. John’s is the perfect choice for an affordable, high-quality private education. Our campus community is diverse and supportive. Our singular approach to education academic study, service opportunities and real-world experience with one of the most far-sighted global studies programs of its kind.
Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.
We focus on three main therapy areas – Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory – and we are also selectively active in the areas of autoimmunity, neuroscience and infection. To put ourselves in the best position to push the boundaries of science, we seek to leverage our combination of capabilities, which encompass both small molecules and biologics, and include immunotherapies and developing innovative delivery devices that can offer choice to patients. These are reinforced by a strong focus on personalised healthcare capabilities, which aim to match medicines only to those patients who will benefit from them. Our teams also work alongside the world's leading academic and biotech research institutions to stimulate innovation and evaluate emerging technologies such as Modified RNA and CRISPR genome editing.
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, visit www.astrazeneca.com
Leveraging the expertise of our unique multidisciplinary team and our state-of-the-art capabilities in modeling, material science, process design, quality assurance and control, we redefine current thinking in the field of healthcare offering cutting-edge, scientific solutions tailored to customer needs.
RCPE’s services encompass the entire value chain of pharmaceutical product development: continuous API synthesis, advanced formulations, next-generation manufacturing, and also device design and optimization.
As a non-profit, private company owned by Graz University of Technology (65%), University of Graz (20%) and Joanneum Research GmbH (15%), we link outstanding science, application and industry in a business-oriented approach.
We supply the pharmaceutical and health care industry with branded and custom respiratory medical devices and solutions to help ease the burden that respiratory challenges bring to patients and their caregivers.
Our innovation focus is to develop products that improve patient outcomes and contribute to health system savings overall.
As a member of our team, you’ll help deliver on our mission to strive for better health and a brighter future for people worldwide through leading innovation in medicine. It’s a responsibility that motivates and inspires us all.
You’ll find your own professional inspiration at Takeda, in the area that suits your interests and skills. Whether that’s R&D, Oncology, Corporate, Manufacturing, Quality, or another business unit, wherever you find yourself at Takeda, you’ll enjoy a meaningful career that’s making a positive impact on patients, people and the planet.
Our skill within the Mass Spectrometry field has allowed us to support clients within a wide range of market sectors including Pharmaceuticals, Tobacco, Next Generation Nicotine products, Consumer products, Polyurethane Foam, Agrochemicals, Persistent Organic Pollutants and much more.
Our approach to supporting clients is simple and well defined - understand your needs and exceed your expectations.
We pride ourselves in not just delivering data but using our extensive understanding of chemistry, chromatography and mass spectrometry combined with our understanding of your application to provide you with answers.
Their laboratories operate to the highest standards and in accordance with ISO, GMP, GLP and FDA regulations. Drawing on a proven 20-year track record of scientific excellence, they provide integrated services to develop, analyze and test a wide range of biological and chemical substances, enabling our customers to bring safer and better products to the market faster.
Chiesi is the largest global pharmaceutical Group to be awarded B Corp Certification, a recognition of high social and environmental standards. We want to use business as a force for good and create a positive impact on people, environment and community.